Endo International PLC  

(Public, NASDAQ:ENDP)   Watch this stock  
Find more results for ENDP
61.97
-0.05 (-0.08%)
Real-time:   3:22PM EDT
NASDAQ real-time data - Disclaimer
Currency in USD
Range 60.19 - 62.31
52 week 32.66 - 82.16
Open 61.00
Vol / Avg. 1.68M/3.32M
Mkt cap 9.41B
P/E     -
Div/yield     -
EPS -4.73
Shares 151.77M
Beta 1.00
Inst. own 92%
May 19, 2014
Endo Health Solutions Inc. Annual Shareholder Meeting (Estimated) Add to calendar
May 1, 2014
Q1 2014 Endo Health Solutions Inc. Earnings Release - 9:30AM EDT - Add to calendar
May 1, 2014
Q1 2014 Endo International PLC Earnings Conference Call - 7:30AM EDT - Add to calendar
Feb 28, 2014
Q4 2013 Endo Health Solutions Inc. Earnings Release
Feb 28, 2014
Q4 2013 Endo Health Solutions Inc. Earnings Conference Call - Webcast
Feb 24, 2014
Paladin Labs Inc Extraordinary Special Meeting Shareholder Meeting
More events from DailyFinance »    

Key stats and ratios

Q4 (Dec '13) 2013
Net profit margin -155.72% -20.46%
Operating margin -168.60% -14.77%
EBITD margin - 35.98%
Return on average assets -40.06% -8.15%
Return on average equity -272.58% -66.98%
Employees 3,371 -
CDP Score - -

Address

25-28 North Wall Quay, DUBLIN 1
DUBLIN,
Ireland
+353-1-6492000 (Phone)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Endo International PLC, formerly Endo Health Solutions Inc., incorporated on November 18, 1997, is a specialty healthcare solutions company focused on branded and generic pharmaceuticals, devices and services. The Company has a portfolio of branded pharmaceuticals that includes brands, such as Lidoderm , Opana ER, Voltaren Gel, Percocet , Frova , Supprelin LA, Vantas , Valstar and Fortesta Gel. The Company operates in three segments: Endo Pharmaceuticals, Qualitest and AMS. In April 2014, the Company acquired worldwide rights to Sumavel DosePro (sumatriptan injection) for subcutaneous use, a needle-free delivery system for sumatriptan, from Zogenix, Inc.